- ►annals.org WJ Sandborn, P Rutgeerts, R Enns, SB … - Annals of internal medicine, 2007 - Am Coll Physicians Background: Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is
an effective treatment for patients with Crohn disease who are naive to the
chimeric TNF antagonist, infliximab. No anti-TNF agent has been evaluated ... Cited by 182 - Related articles - BL Direct - All 7 versions
WJ Sandborn, SB Hanauer, P Rutgeerts, RN … - British Medical Journal, 2007 - gut.bmj.com Methods: In the preceding CLASSIC I trial, 299 patients with moderate to severe
Crohn's disease naive to tumour necrosis factor antagonists received induction
therapy with adalimumab 40 mg/20 mg, 80 mg/40 mg, or 160 mg/80 mg, or ... Cited by 165 - Related articles - BL Direct - All 4 versions
JF Colombel, WJ Sandborn, P Rutgeerts, R … - Gastroenterology, 2007 - Elsevier Background & Aims: This study evaluated the efficacy and safety of adalimumab, a
fully human, anti–tumor necrosis factor monoclonal antibody administered
subcutaneously, in the maintenance of response and remission in patients ... Cited by 329 - Related articles - All 20 versions
- ►rima.org [PDF] SB Hanauer, WJ Sandborn, P Rutgeerts, RN … - Gastroenterology, 2006 - Elsevier Background & Aims: Tumor necrosis factor blockade has been shown to be an
effective treatment strategy in Crohn's disease (CD). Adalimumab is a human
immunoglobulin G1 (IgG 1 ) monoclonal antibody targeting tumor necrosis ... Cited by 365 - Related articles - All 13 versions
WJ Sandborn, BG Feagan, S Stoinov, PJ … - The New England journal of medicine, 2007 - nejm.highwire.org From the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
(WJS); the University of Western Ontario, London, ON, Canada (BGF); Clinic of
Gastroenterology, Multiprofile Hospitals for Active Treatment Queen Ioanna, ... Cited by 177 - Related articles - BL Direct - All 6 versions
S Schreiber, M Khaliq-Kareemi, IC Lawrance … - The New England journal of medicine, 2007 - nejm.highwire.org From the Hospital for General Internal Medicine, Christian Albrechts University,
Kiel, Germany (SS); Dalhousie University, Halifax, NS, Canada (MK-K.); School of
Medicine and Pharmacology, University of Western Australia, Fremantle ... Cited by 196 - Related articles - BL Direct - All 7 versions
- ►thelancet.com G D'Haens, F Baert, G van Assche, P … - The Lancet, 2008 - Elsevier We did a 2-year open-label randomised trial at 18 centres in Belgium, Holland,
and Germany between May, 2001, and January, 2004. We randomly assigned 133
patients to either early combined immunosuppression or conventional ... Cited by 117 - Related articles - All 8 versions
SR Targan, BG Feagan, RN Fedorak, BA … - Gastroenterology, 2007 - Elsevier Background & Aims: A randomized placebo-controlled trial evaluated the efficacy
of natalizumab induction therapy in patients with Crohn's disease. Methods:
Patients (N = 509) with moderately to severely active Crohn's disease and ... Cited by 86 - Related articles - All 7 versions
J Hinojosa, F Gomollon, S Garcia, G Bastida, … - Alimentary Pharmacology and Therapeutics, 2007 - phx1.medscape.com Adalimumab is a fully human IgG 1 monoclonal antibody to TNF that has also been
shown to induce and maintain clinical response or remission in patients with
active inflammatory CD. [19-21] Preliminary evidence indicates that ... Cited by 35 - Related articles - BL Direct - All 11 versions
